DENVER, Colo., Jun 17, 2024 (247marketnews.com)- Mustang Bio, Inc. (Nasdaq:MBIO) presented positive updated data from its ongoing Phase 1/2 MB-106, a CD20-targeted, autologous CAR T-cell therapy, clinical trial, which shows a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer, at the European Hematology Association 2024 Hybrid Congress (EHA2024).
Brian Till, M.D., Associate Professor and physician at Fred Hutch and University of Washington, stated, “We are very encouraged by the safety and efficacy data generated in WM, along with improvements in the quality of responses over time, which demonstrates MB-106 CAR T-cell expansion and persistence.”
The post Mustang Bio Presents Favorable Phase 1/2 MB-106 Clinical Trial Data at EHA2024 appeared first on 24/7 MarketNews.
Login